News

January 29, 2018

29th January 2018, Seattle, United States of America –The Benaroya Research Institute in Seattle announced receipt of National Institute of Health funding to support investigations into the immune mechanisms of PVX108. The research group led by Erik Wambre (PhD) from t...

January 13, 2018

13th January 2018, California, United States of America – Australian biotechnology company Aravax presented preliminary data from the first Phase I clinical trial of its product known as PVX108 at the  Gordon Research Conference on Food Allergy at Ventura Beach in Cali...

January 9, 2018

9th January 2018, California, United States of America – Aravax, an Australian biotechnology company revolutionising peanut allergy treatment, today held the first meeting of its newly appointed Scientific Advisory Board, at the Gordon’s Research Conference on Food All...

November 17, 2017

17th November 2017 – Aravax today signed a collaborative agreement with Stanford University in California. The Stanford research group, led by Professor Kari Nadeau, will collaborate with Aravax to further explore immunological responses to Aravax's revolutionary peanu...

May 16, 2017

16 May 2017, Melbourne, Victoria – Australian biotechnology company Aravax has commenced clinical trials of a potentially life-changing product developed to treat sufferers of peanut allergy.

Aravax’s technology uses carefully selected fragments of peanut proteins to...

Please reload

Archive
Please reload

Aravax


Tel: +61 (0)3 9657 0700
Email: info@aravax.com.au​
Address: Level 9, 31 Queen St

Melbourne, Victoria, 3000

Australia

Contact Us